BioCentury | Mar 2, 2021
Regulation

Novavax preps for Q2 COVID vaccine EUA submission; plus Fibrogen, Inovio, J&J, Aslan, Merck, Oncopeptides and Athenex

...overall survival in the confirmatory Phase III KEYNOTE-604 study.Setback for Athenex in breast cancerShares of Athenex Inc....
...million follow-on.TARGETSIL-13R – Interleukin-13 receptor BC Staff Keytruda, pembrolizumab (MK-3475, lambrolizumab) Evrenzo, roxadustat (ASP1517, FG-4592) NVX-CoV2373 Oncopeptides AB Merck & Co. Inc. Athenex Inc. FibroGen...
BioCentury | Feb 19, 2021
Finance

Canada’s Sagard tops off royalty fund at $725M, beating goal

...treat ovarian cancer. It also will hold temporary rights to royalties tied to oral paclitaxel from Athenex Inc....
BioCentury | Sep 2, 2020
Regulation

Sept. 1 Quick Takes: House committee to subpoena AbbVie on pricing; plus Athenex, Harmony, AZ, BMS, Novo, and cancer trial guidance

...and cancer therapy Imbruvica ibrutinib. The pharma dipped $3.56 to $92.24 on Tuesday.Priority Review for Athenex’s...
...therapyFDA accepted and granted Priority Review to an NDA for oral paclitaxel and encequidar from Athenex Inc....
...committee meeting to discuss the therapy, which has a PDUFA date of Feb. 28, 2021. Athenex...
BioCentury | Aug 7, 2020
Finance

Aug. 6 Quick Takes: More pressure on China’s U.S. listings; busy Editas; Athenex bestows royalty on Sagard; Longwood, CFF launch incubator and more

...Thursday’s regular session; Beam rose $3.24 (15%) to $24.52. Sagard in royalty deal with Athenex Athenex Inc....
...its oral paclitaxel to treat metastatic breast cancer in exchange for a temporary single-digit royalty. Athenex...
...a royalty stream tied to Rubraca rucaparib from Clovis Oncology Inc. (NASDAQ:CLVS). Ladenburg Thalmann advised Athenex...
BioCentury | Jun 26, 2020
Management Tracks

Saunders joins BridgeBio’s board; plus changes at BioXcel, FibroGen, Storm, Athenex, Seres, Chimerix and Catalyst

...Calypso Biotech B.V. and serves as a medical adviser to the European Commission. Cancer company Athenex Inc....
...patient services from senior director of patient services. Robin Sawka, BioCentury Staff BridgeBio Pharma Inc. FibroGen Inc. Storm Therapeutics Ltd. Athenex Inc. Seres...
BioCentury | Dec 6, 2019
Financial News

Financing Roundup: Immunomedics, Ardelyx, Millendo, Omeros, Athenex

...Wednesday, Immunomedics, Ardelyx, Millendo and Omeros raised a total of $450 million in follow-ons, while Athenex...
...treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (see “Omeros’ Narsoplimab Headed for 1H20 Submission” ). Athenex Inc....
...The deal was underwritten by SunTrust Robinson Humphrey. Val Kennedy, Associate Editor Immunomedics Inc. Ardelyx Inc. Millendo Therapeutics Inc. Omeros Corp. Athenex Inc. Kyowa...
BioCentury | Sep 4, 2019
Company News

Management tracks: PhRMA, Arcus, Beam, Stealth, Bolt, Athenex, Click, Melinta, Kallyope and Genor

...He was president and CEO, as well as a co-founder, of Alder BioPharmaceuticals Inc. (NASDAQ:ALDR). Athenex Inc....
...Ltd., a HillHouse Capital affiliated fund. Hongjiang Li, Staff Writer and Mary Romeo, Assistant Editor Arcus Biosciences Inc. Athenex Inc. Bolt...
BioCentury | Aug 7, 2019
Clinical News

Aug. 7 Clinical Quick Takes: Waylivra cuts triglycerides in Phase III; plus Lynparza, Moderna, Athenex and Opthea

...in the clinic, gained $0.56 to $12.85 on Wednesday. Athenex tumbles after breast cancer data Athenex Inc....
...overall response rate of 36% vs. 24% for IV paclitaxel (p=0.01) in the intent-to-treat population. Athenex...
...Compound #), rhuFab V2 (Former compound #), ranibizumab (Generic), Lucentis (Informal) Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) OPT-302, vgx-300 Oraxol Athenex Inc. Ionis...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...from Deciphera Pharmaceuticals Inc.'s ripretinib to treat gastrointestinal cancer (GIST). Another pick of Borho’s is Athenex Inc....
...Thousand Oaks, Calif. AnaptysBio Inc. (NASDAQ:ANAB), San Diego, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Athenex Inc....
BioCentury | May 6, 2019
Financial News

May 6 Financial Quick Takes: Athenex, Spiral

...to fund commercialization activities for Oraxol and advance its oncology pipeline and actinic keratosis therapy, Athenex Inc....
...of paclitaxel and encequidar (HM30181A), is in Phase III testing for breast and gastric cancer. Athenex...
...Savoir Capital and Camden Partners participated in the hearing loss company’s first tranche. Hongjiang Li, Staff Writer Oraxol Athenex Inc. Spiral...
Items per page:
1 - 10 of 74
BioCentury | Mar 2, 2021
Regulation

Novavax preps for Q2 COVID vaccine EUA submission; plus Fibrogen, Inovio, J&J, Aslan, Merck, Oncopeptides and Athenex

...overall survival in the confirmatory Phase III KEYNOTE-604 study.Setback for Athenex in breast cancerShares of Athenex Inc....
...million follow-on.TARGETSIL-13R – Interleukin-13 receptor BC Staff Keytruda, pembrolizumab (MK-3475, lambrolizumab) Evrenzo, roxadustat (ASP1517, FG-4592) NVX-CoV2373 Oncopeptides AB Merck & Co. Inc. Athenex Inc. FibroGen...
BioCentury | Feb 19, 2021
Finance

Canada’s Sagard tops off royalty fund at $725M, beating goal

...treat ovarian cancer. It also will hold temporary rights to royalties tied to oral paclitaxel from Athenex Inc....
BioCentury | Sep 2, 2020
Regulation

Sept. 1 Quick Takes: House committee to subpoena AbbVie on pricing; plus Athenex, Harmony, AZ, BMS, Novo, and cancer trial guidance

...and cancer therapy Imbruvica ibrutinib. The pharma dipped $3.56 to $92.24 on Tuesday.Priority Review for Athenex’s...
...therapyFDA accepted and granted Priority Review to an NDA for oral paclitaxel and encequidar from Athenex Inc....
...committee meeting to discuss the therapy, which has a PDUFA date of Feb. 28, 2021. Athenex...
BioCentury | Aug 7, 2020
Finance

Aug. 6 Quick Takes: More pressure on China’s U.S. listings; busy Editas; Athenex bestows royalty on Sagard; Longwood, CFF launch incubator and more

...Thursday’s regular session; Beam rose $3.24 (15%) to $24.52. Sagard in royalty deal with Athenex Athenex Inc....
...its oral paclitaxel to treat metastatic breast cancer in exchange for a temporary single-digit royalty. Athenex...
...a royalty stream tied to Rubraca rucaparib from Clovis Oncology Inc. (NASDAQ:CLVS). Ladenburg Thalmann advised Athenex...
BioCentury | Jun 26, 2020
Management Tracks

Saunders joins BridgeBio’s board; plus changes at BioXcel, FibroGen, Storm, Athenex, Seres, Chimerix and Catalyst

...Calypso Biotech B.V. and serves as a medical adviser to the European Commission. Cancer company Athenex Inc....
...patient services from senior director of patient services. Robin Sawka, BioCentury Staff BridgeBio Pharma Inc. FibroGen Inc. Storm Therapeutics Ltd. Athenex Inc. Seres...
BioCentury | Dec 6, 2019
Financial News

Financing Roundup: Immunomedics, Ardelyx, Millendo, Omeros, Athenex

...Wednesday, Immunomedics, Ardelyx, Millendo and Omeros raised a total of $450 million in follow-ons, while Athenex...
...treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (see “Omeros’ Narsoplimab Headed for 1H20 Submission” ). Athenex Inc....
...The deal was underwritten by SunTrust Robinson Humphrey. Val Kennedy, Associate Editor Immunomedics Inc. Ardelyx Inc. Millendo Therapeutics Inc. Omeros Corp. Athenex Inc. Kyowa...
BioCentury | Sep 4, 2019
Company News

Management tracks: PhRMA, Arcus, Beam, Stealth, Bolt, Athenex, Click, Melinta, Kallyope and Genor

...He was president and CEO, as well as a co-founder, of Alder BioPharmaceuticals Inc. (NASDAQ:ALDR). Athenex Inc....
...Ltd., a HillHouse Capital affiliated fund. Hongjiang Li, Staff Writer and Mary Romeo, Assistant Editor Arcus Biosciences Inc. Athenex Inc. Bolt...
BioCentury | Aug 7, 2019
Clinical News

Aug. 7 Clinical Quick Takes: Waylivra cuts triglycerides in Phase III; plus Lynparza, Moderna, Athenex and Opthea

...in the clinic, gained $0.56 to $12.85 on Wednesday. Athenex tumbles after breast cancer data Athenex Inc....
...overall response rate of 36% vs. 24% for IV paclitaxel (p=0.01) in the intent-to-treat population. Athenex...
...Compound #), rhuFab V2 (Former compound #), ranibizumab (Generic), Lucentis (Informal) Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) OPT-302, vgx-300 Oraxol Athenex Inc. Ionis...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...from Deciphera Pharmaceuticals Inc.'s ripretinib to treat gastrointestinal cancer (GIST). Another pick of Borho’s is Athenex Inc....
...Thousand Oaks, Calif. AnaptysBio Inc. (NASDAQ:ANAB), San Diego, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Athenex Inc....
BioCentury | May 6, 2019
Financial News

May 6 Financial Quick Takes: Athenex, Spiral

...to fund commercialization activities for Oraxol and advance its oncology pipeline and actinic keratosis therapy, Athenex Inc....
...of paclitaxel and encequidar (HM30181A), is in Phase III testing for breast and gastric cancer. Athenex...
...Savoir Capital and Camden Partners participated in the hearing loss company’s first tranche. Hongjiang Li, Staff Writer Oraxol Athenex Inc. Spiral...
Items per page:
1 - 10 of 74